Michelle G Cheng

US Patent:

8101158, Jan 24, 2012

Filed:

Feb 4, 2008

Appl. No.:

12/025673

Inventors:

Alex G. Lee - Palo Alto CA, US
Michelle Y. Cheng - Monterey Park CA, US
Robert M. Sapolsky - San Francisco CA, US

Assignee:

The Regents of the University of California - Oakland CA
Stanford University - Stanford CA

International Classification:

A61K 49/00
A61K 31/535

US Classification:

424 91, 5142312

Abstract:

The present invention relates to a method of identifying agents that modulate prokineticin receptors, particularly, in the brain. Such agents are useful in the treatment of cerebrovascular diseases, including cerebral ischemia, cerebral hemorrhage, ischemic stroke, hemorrhagic stroke, and ischemic reperfusion injury. Additionally, such agents are useful to treat seizure disorders, such as epilepsy.

US Patent:

20040229291, Nov 18, 2004

Filed:

Oct 3, 2003

Appl. No.:

10/680554

Inventors:

Michelle Cheng - Irvine CA, US

International Classification:

G01N033/53
G01N033/567
A61K038/17

US Classification:

435/007200, 514/012000

Abstract:

The invention provides methods of identifying compounds that modulate neurogenesis. The methods involve providing a compound that modulates prokineticin receptor signaling; contacting a neural stem or progenitor cell with the compound; and determining the ability of the compound to modulate neurogenesis. The invention also provides methods for modulating neurogenesis. The methods involve contacting a neural stem or progenitor cell with an effective amount of a compound that modulates prokineticin receptor signaling. Such methods are useful for both ex vivo or in vivo therapeutic applications where neural regeneration is desirable.